Effect of frailty on prognosis in patients with metastatic urothelial carcinoma(FRAmUC study)

An observational study of the effect of frailty on prognosis in patients with metastatic urothelial carcinoma(FRA-mUC study) - An observational study of the effect of frailty on prognosis in patients with metastatic urothelial carcinoma(FRA-mUC study)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039881

Enrollment

200

Registered

2020-03-20

Start date

2017-01-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic urothelial carcinoma

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients with metastatic urothelial carcinoma who were 1) treated with standard of care,2) evaluated with frailty

Exclusion criteria

Exclusion criteria: Patients with metastatic urothelial carcinoma who were not treated with standard of care or no frailty evaluation.

Design outcomes

Primary

Measure	Time frame
The primary outcome was the effect of frailty on progression-free survival in patients with metastatic urothelial carcinoma	—

Secondary

Measure	Time frame
Secondary outcomes included safety, progression-free survival, and overall survival.	—

Countries

Japan

Contacts

Public ContactShingo Hatakeyama

Hirosaki University School of Medicine Urology

shingorilla2@gmail.com0172395091

Outcome results